CellCentric Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.cellcentric.com
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1
Recruiting
- Conditions
- Non Hodgkin LymphomaHaematological MalignancyAcute Myeloid LeukemiaHigher-risk Myelodysplastic SyndromeMultiple MyelomaPeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04068597
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇺🇸The Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland, United States
Study to Evaluate CCS1477 in Advanced Tumours
Phase 1
Active, not recruiting
- Conditions
- Metastatic Castration-Resistant Prostate CancerNon-small Cell Lung CancerMetastatic Breast CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT03568656
- Locations
- 🇫🇷
Institute Gustave Roussy, Villejuif, France
🇳🇱Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
🇪🇸Hospital Vall d'Hebron, VHIO, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath